Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The ENACT Trial: A Randomized, Double-blind, Placebo-controlled Adjunctive Treatment Trial to Evaluate the Efficacy and Safety of ENX-101 in Patients With Focal (Partial Onset) Seizures

NCT05481905 is registered in ClinicalTrials.gov with Engrail Therapeutics INC as lead sponsor.

NCT NCT05481905
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05481905 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The ENACT Trial: A Randomized, Double-blind, Placebo-controlled Adjunctive Treatment Trial to Evaluate the Efficacy and Safety of ENX-101 in Patients With Focal (Partial Onset) Seizures
Lead sponsor
Engrail Therapeutics INC
Phase
Phase 2
Overall status
Withdrawn
Start date
September 30, 2022
Completion date
December 31, 2024
Enrollment
0 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

focal epilepsy